Related references
Note: Only part of the references are listed.Reconstruction of LPS Transfer Cascade Reveals Structural Determinants within LBP, CD14, and TLR4-MD2 for Efficient LPS Recognition and Transfer
Je-Kyung Ryu et al.
IMMUNITY (2017)
Leucine-rich repeat 2 of human Toll-like receptor 4 contains the binding site for inhibitory monoclonal antibodies
Hiroki Tsukamoto et al.
FEBS LETTERS (2015)
Robust Antibody-Antigen Complexes Prediction Generated by Combining Sequence Analyses, Mutagenesis, In Vitro Evolution, X-ray Crystallography and In Silico Docking
Jeremy Loyau et al.
JOURNAL OF MOLECULAR BIOLOGY (2015)
Control of adaptive immunity by the innate immune system
Akiko Iwasaki et al.
NATURE IMMUNOLOGY (2015)
Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors
Jeremy Loyau et al.
MABS (2014)
Multiple roles of toll-like receptor 4 in colorectal cancer
Dhanusha Yesudhas et al.
FRONTIERS IN IMMUNOLOGY (2014)
Immunotherapy for the Adjunctive Treatment of Sepsis: From Immunosuppression to Immunostimulation Time for a Paradigm Change?
Jenneke Leentjens et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
MD-2-dependent human Toll-like receptor 4 monoclonal antibodies detect extracellular association of Toll-like receptor 4 with extrinsic soluble MD-2 on the cell surface
Hiroki Tsukamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis The ACCESS Randomized Trial
Steven M. Opal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Reduced Surface Expression of TLR4 by a V254I Point Mutation Accounts for the Low Lipopolysaccharide Responder Phenotype of BALB/c B Cells
Hiroki Tsukamoto et al.
JOURNAL OF IMMUNOLOGY (2013)
Discovery and Validation of a New Class of Small Molecule Toll-Like Receptor 4 (TLR4) Inhibitors
Matthew D. Neal et al.
PLOS ONE (2013)
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
Richard S. Hotchkiss et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists
Francesco Peri et al.
BIOTECHNOLOGY ADVANCES (2012)
Multiple potential regulatory sites of TLR4 activation induced by LPS as revealed by novel inhibitory human TLR4 mAbs
Hiroki Tsukamoto et al.
INTERNATIONAL IMMUNOLOGY (2012)
Myeloid differentiation 2 as a therapeutic target of inflammatory disorders
Sun Hong Park et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
Taro Kawai et al.
IMMUNITY (2011)
Toll like receptor 4 in atherosclerosis and plaque destabilization
Wijnand K. den Dekker et al.
ATHEROSCLEROSIS (2010)
Lipopolysaccharide-binding protein-mediated Toll-like receptor 4 dimerization enables rapid signal transduction against lipopolysaccharide stimulation on membrane-associated CD14-expressing cells
Hiroki Tsukamoto et al.
INTERNATIONAL IMMUNOLOGY (2010)
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Taro Kawai et al.
NATURE IMMUNOLOGY (2010)
Free Thiol Group of MD-2 as the Target for Inhibition of the Lipopolysaccharide-induced Cell Activation
Mateja Mancek-Keber et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex
Beom Seok Park et al.
NATURE (2009)
Pivotal involvement of Fcγ receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1
Irene Dunn-Siegrist et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock
Bruno Daubeuf et al.
JOURNAL OF IMMUNOLOGY (2007)
Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2
A Visintin et al.
JOURNAL OF IMMUNOLOGY (2005)
The functional and structural properties of MD-2 required for lipopolysaccharide binding are absent in MD-1
N Tsuneyoshi et al.
JOURNAL OF IMMUNOLOGY (2005)
Inhibition of endotoxin response by E5564, a novel toll-like receptor 4-directed endotoxin antagonist
M Mullarkey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Share Paper
